PDF herunterladen
Thromb Haemost 1998; 79(02): 331-337
DOI: 10.1055/s-0037-1614987
Letters to the Editor
Schattauer GmbH

Characterization of Soluble Thrombomodulin Fragments in Human Urine

Masahiko Nakano
1   From Niigata Research Laboratory, Mitsubishi Gas Chemical Company, Inc., Tayuhama, Japan
,
Masayuki Furutani
1   From Niigata Research Laboratory, Mitsubishi Gas Chemical Company, Inc., Tayuhama, Japan
,
Sayuri Hiraishi
2   From Department of Clinical Biochemistry, Faculty of Pharmaceutical Sciences, Teikyo University, Japan
,
Hidemi Ishii
3   From Department of Public Health, Showa College of Pharmaceutical Sciences, Higashi Tamagawa Gakuen, Machida, Tokyo, Japan
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 04. April 1997

Accepted after resubmission 29. September 1997

Publikationsdatum:
08. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

The soluble thrombomodulin (TM) subspecies in human urine detected by polyclonal anti-human TM IgG were isolated and characterized. 105, 85, 80, 56, 33, 31 and 28 kDa subspecies under reducing conditions was comparable to 78, 66, 56, 200, 52, 30 and 25 kDa under non-reducing conditions, respectively, in the two-dimensional electrophoresis. Each subspecies under non-reducing conditions, except the 200 and 52 kDa molecules, was constituted of single subspecies, whereas the 200 and 52 kDa molecules were constituted of the tetramer of the 56 kDa subspecies of reducing conditions and a dimer of the 33 kDa subspecies, respectively. NH2-terminal amino acid sequences of the 105, 85 and 80 kDa subspecies maintained Ala1-Pro2-Ala3- of intact human TM, however, 56, 33, 31 and 28 kDa subspecies started from Glu137-Gln138-, Gln214-Gly215-, Ser228-Val229- and Ala240-Ile241-, respectively. All subspecies obtained under non-reducing conditions exhibited cofactor activity for thrombin-dependent protein C activation ranging from 58 to 162 pmol APC/min/nmol TM at 0.4 mM Ca2+ indicating that all of the subspecies maintained the fourth to sixth repeat of epidermal growth factor-like structure of intact TM. 85, 80, 56, 33, 31 and 28 kDa subspecies were suggested to lack both chondroitin sulfate glycosaminoglycan (CSGAG), transmembrane and cytoplasmic domains of intact TM, while 105 kDa subspecies lack only CSGAG from the results of kinetic properties and the interaction with phospholipid vesicles composed from phosphatidylcholine and phosphatidylethanolamine.

 

  • References

  • 1 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-52.
    CrossrefPubMedGoogle Scholar
  • 2 Esmon CT. The role of protein C and TM in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
    PubMedGoogle Scholar
  • 3 Dittman WA, Majerus PW. Structure and function of TM; A natural anticoagulant. Blood 1990; 75: 329-36.
    PubMedGoogle Scholar
  • 4 Maruyama I, Bell CE, Majerus PW. TM is found on endothelium of arteries, veins, capillaries, lymphatics, and syncytiotrophoblast of human placenta. J Cell Biol 1985; 101: 363-71.
    CrossrefPubMedGoogle Scholar
  • 5 Suzuki K, Kusumoto S, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human TM, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987; 6: 1891-7.
    PubMedGoogle Scholar
  • 6 Suzuki K, Hayashi T, Nishioka J, Kosaka Y, Zushi M, Honda G, Yamamoto S. A domain composed of epidermal growth factor-like structures of human TM is essential for thrombin binding and protein C activation. J Biol Chem 1989; 264: 4872-6.
    PubMedGoogle Scholar
  • 7 Hayashi T, Suzuki K. Monoclonal antibodies for human TM which recognize binding sites for thrombin and protein C. J Biochem (Tokyo) 1990; 108: 874-8.
    CrossrefPubMedGoogle Scholar
  • 8 Bourin MC, Ohlin AK, Lane DA, Stenfro J, Lindahl U. Relationship between anticoagulant activities and polyanionic properties of rabbit thrombomodulin. J Biol Chem 1988; 263: 8044-52.
    PubMedGoogle Scholar
  • 9 Lin JH, McLean K, Morser J, Young TA, Wydro RM, Andrews WH, Light DR. Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem 1994; 269: 25021-30.
    PubMedGoogle Scholar
  • 10 Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin-TM complex. Biochem J 1986; 238: 151-7.
    CrossrefPubMedGoogle Scholar
  • 11 Galvin JB, Kurosawa S, Moore K, Esmon CT, Esmon NL. Reconstitution of rabbit TM into phospholipid vesicles. J Biol Chem 1987; 262: 2199-205.
    PubMedGoogle Scholar
  • 12 Horie S, Ishii H, Hara H, Kazama M. Enhancement of thrombin-TMcatalysed protein C activation by phosphatidylethanolamine containing unsaturated fatty acids: possible physiological significance of phosphatidylethanolamine in anticoagulant activity of TM. Biochem J 1994; 301: 683-91.
    CrossrefPubMedGoogle Scholar
  • 13 Ishii H, Majerus PW. TM is present in human plasma and urine. J Clin Invest 1985; 76: 2178-81.
    CrossrefPubMedGoogle Scholar
  • 14 Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hiraishi S, Tahara C, Miyajima Y, Kazama M. Establishment of enzyme immunoassay of human TM in plasma and urine using monoclonal antibodies. Thromb Haemost 1990; 63: 157-62.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Ishii H, Uchiyama H, Kazama M. Soluble TM antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-23.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 16 Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased TM values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37: 269-72.
    PubMedGoogle Scholar
  • 17 Kazama M. Clinical elevation of hemostatic molecular markers. Acta Hematol 1988; 51: 1387-94.
    PubMedGoogle Scholar
  • 18 Takano S, Kimura S, Ohdama S, Aoki N. Plasma TM in health and diseases. Blood 1990; 76: 2024-9.
    PubMedGoogle Scholar
  • 19 Ishii H. The detection and measurement of thrombomodulin. In: Thrombin, Thrombomodulin and the Control of Hemostasis. Giddings JC. ed. R. G. Landes Company; Austin: 1994. pp 121-41.
    Google Scholar
  • 20 Yoshida M, Kozaki M, Ioya N, Kaji N, Tamaki T, Hiraishi S, Ishii H, Kazama M, Fukutomi K, Nagasawa T. Plasma thrombomodulin levels as an indicator of vascular injury caused by cyclosporine nephrotoxicity. Transplantation 1990; 50: 1066-9.
    CrossrefPubMedGoogle Scholar
  • 21 Yamamoto S, Mizoguchi T, Tamaki T, Ohkuchi M, Kimura S, Aoki N. Urinary TM, its isolation and characterization. J Biochem 1993; 113: 433-40.
    CrossrefPubMedGoogle Scholar
  • 22 Jackson DE, Tetaz TJ, Salem HH, Mitchell CA. Purification and characterization of two form of soluble TM from human urine. Eur J Biochem 1994; 221: 1079-87.
    CrossrefPubMedGoogle Scholar
  • 23 Takahashi Y, Hosaka Y, Niina H, Nagasawa K, Naotsuka M, Sakai K, Uemura A. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo. Thromb Haemost 1995; 73: 805-11.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Nawa K, Sakano K, Fujiwara H, Sato Y, Sugiyama N, Teruuchi T, Iwamoto M, Marumoto Y. Presence and function of chondroitin-4-sulfate on recombinant human soluble thrombomodulin. Biochem Biophys Res Commun 1990; 171: 729-37.
    CrossrefPubMedGoogle Scholar
  • 25 Laemmli VK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
    CrossrefPubMedGoogle Scholar
  • 26 Salem HH, Maruyama I, Ishii H, Majerus PW. Isolation and characterization of TM from human placenta. J Biol Chem 1984; 259: 12246-51.
    PubMedGoogle Scholar
  • 27 Johnson AE, Esmon NL, Laue TM, Esmon CT. Structural changes required for activation of protein C are induced by Ca2+ binding to a high-affinity site that does not contain -carboxyglutamic acid. J Biol Chem 1983; 258: 5554-60.
    PubMedGoogle Scholar
  • 28 Kurosawa S, Galvin JB, Esmon NL, Esmon CT. Proteolytic formation and properties of functional domains of thrombomodulin. J Biol Chem 1987; 262: 2206-12.
    PubMedGoogle Scholar
  • 29 Parkinson JF, Grinnell BW, Moore RE, Hoskins J, Vlahos CJ, Bang NU. Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells. J Biol Chem 1990; 265: 12602-10.
    PubMedGoogle Scholar
  • 30 Zushi M, Gomi K, Honda G, Kondo S, Yamamoto S, Hayashi T, Suzuki K. Aspartic acid 349 in the fourth epidermal growth factor-like structure of human thrombomodulin plays a role in its Ca2+-mediated binding to protein C. J Biol Chem 1991; 266: 19886-9.
    PubMedGoogle Scholar
  • 31 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
    PubMedGoogle Scholar
  • 32 Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
    CrossrefPubMedGoogle Scholar
  • 33 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
    CrossrefPubMedGoogle Scholar
  • 34 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascade through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
    CrossrefPubMedGoogle Scholar
  • 35 Ishii H, Hosaka Y. Soluble forms of thrombomodulin in human plasma participate to inhibition of fibrinolysis more than coagulation. Thromb Haemost 1997; XVI Congress (Abstracts) 548.
    PubMedGoogle Scholar
  • 36 Redlits A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidase as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-3.
    CrossrefPubMedGoogle Scholar